衰老 雷帕黴素是一種通用的抗衰老藥物嗎？

神祕奧祕 理解宇宙的神祕奧祕 在腦袋中的腦癌患者中 MTOR激活標記被發現 是百分之一百倍高於 年齡相符的腦袋患者 死亡的其他原因 這是合理的 由於腦部細胞不太容易分裂 一旦它們成長 這會導致腦部細胞損壞 導致腦部細胞損壞 腦部細胞損壞是非常重要的 由於腦部細胞腫脹 腦部細胞腫脹 研究顯示 在腦內脈腫腺病的 腕臟模型中 腦部細胞腫脹 代表腦部細胞腫脹 由於腦部細胞腫脹 腦部細胞腫腹 由於腦部細胞腫腹 腦部細胞腫腹 由於腦部細胞腫腹 700-fold from age 55 to 85. Unfortunately, no such clinical trial has been attempted. It doesn't even look like the dementia rates of organ transplant patients given rapamycin have ever been tracked. When kidney transplant patients are initially switched to mTOR inhibitors, they do seem to experience a significant improvement in executive function, memory, and mood, but that may be in part because they were switching from drugs like cyclosporine, which can on their own cause adverse neuropsychiatric effects. Rapamycin has been off-patent for more than a decade, so drug companies can no longer charge whatever they want. Without such price protection, there isn't a strong profit motive to study the drug, so we shouldn't expect any large clinical trials anytime soon. Another reason for clinical trial hesitancy may be the frequent and sometimes life-threatening side effects, like immunosuppression. In one cancer trial of an mTOR inhibitor, for example, two of the 18 patients developed life-threatening infections, and one of them died. To fight cancer or organ rejection, we may be willing to put up with significant risk, but there's a much lower risk tolerance for anti-aging drugs meant to be used en masse for healthy humans. The mouse longevity trials are impressive, but they're typically performed in a strictly controlled pathogen-free environment that may not translate out into real-world conditions. The immunosuppressive effects alone are considered sufficient to caution against self-experimentation. Nevertheless, there is a clinic devoted to patients who self-medicate with rapamycin in an attempt to slow aging. Rapamycin advocates point out that the doses required for anti-aging are much lower than used in cancer therapy or organ transplantation, and if anything, might rejuvenate immunity. Is it possible that transient and or intermittent dosing could also help reap the benefits without as many risks? You don't know, until you put it to the test. Two small pilot studies of low-dose rapamycin for a few months in the elderly didn't cause any major side effects, though did cause diarrhea in up to 62%, but also failed to find any immediate benefits to cognitive function or physical performance. In 2018, however, hundreds of individuals aged 65 and older were randomized to mTOR inhibition about 100-fold lower than what's used in oncology or transplant patients, and instead of immune suppression, they did appear to get immune rejuvenation. Not only did they experience an improvement in their response to flu vaccination, but they experienced significantly lower infections in the subsequent year compared to placebo, and they only got the drugs for six weeks. This suggests a persistent improvement in immune function months after discontinuing the drug. Still, self-experimentation continues to be strongly discouraged until we have a better idea of the risks. Thankfully, there are ways to suppress mTOR without taking drugs.